WinSanTor

WinSanTor Inc. is a clinical-stage biotechnology company founded in 2011, with a clear mission encapsulated in its slogan: "Working to discover and develop treatments for peripheral neuropathy." The company's focus lies in the discovery and development of treatments for peripheral neuropathies, encompassing conditions such as diabetic peripheral neuropathy, chemo-induced peripheral neuropathy, HIV-induced, and others. This forward-thinking approach is backed by a team of scientific and industry experts who are committed to leveraging recent scientific insights into the biological processes underlying degenerative diseases to develop effective medicines. Notably, WinSanTor has attracted Venture Round investment at 12 February 2019, with Christoph Lymbersky as one of the key investors. This investment served to bolster the company's pursuit of a science-driven approach to translational medicine and clinical development. Operating at the intersection of Biotechnology and Health Care industries, WinSanTor's dedication to addressing a critical medical need is underpinned by its commitment to rigorous scientific and clinical development methodologies.